ProMIS Neurosciences
- Biotech or pharma, therapeutic R&D
ProMIS Neurosciences, Inc. (Nasdaq: PMN) is a biotechnology company leveraging, EpiSelect™, a proprietary discovery platform that enables precision targeting of disease causing epitopes on toxic misfolded proteins to develop highly selective antibody therapeutics for neurodegenerative diseases.
We are focused on the development of antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson's Disease (PD). We are also developing vaccines targeting amyloid-beta (AD prevention) and alpha-synuclein (multiple synucleinopathies). Our proprietary platform is also available for drug discovery partnership.
We are currently running a Ph1b POC clinical trial in AD with our lead antibody, PMN310, and expect interim data in H1 2026, and top-line data by end of 2026. Our pipeline assets are in preclinical stage.
Address
BostonMassachusetts
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}